This is the authors' abstract. We don't add key points for this paper.
Melanocortin receptors (provisional nomenclature as recommended by NC-IUPHAR [41]) are activated by members of the melanocortin family (α-MSH, β-MSH and γ-MSH forms; δ form is not found in mammals) and adrenocorticotrophin (ACTH). Endogenous antagonists include agouti and agouti-related protein. ACTH(1-24) was approved by the US FDA as a diagnostic agent for adrenal function test, whilst NDP-MSH was approved by EMA for the treatment of erythropoietic protoporphyria. Several synthetic melanocortin receptor agonists are under clinical development.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Caruso et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: